



AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA
VERONA



(D.Lgs. n. 517/1999 - Art. 3 L.R. Veneto n. 18/2009)

DIPARTIMENTO AD ATTIVITÀ INTEGRATA MEDICO GENERALE

UNITÀ OPERATIVA COMPLESSA DI GASTROENTEROLOGIA A

Direttore: Dott. Antonio Colecchia

Borgo Trento - P.le A. Stefani, 1 - 37126 Verona - Tel. 045 812 2310 - 045 812 2489 - Fax 045 812 2014

e-mail: gastroenterologia.a@aovr.veneto.it

Ms Ref. n. 64647

Title: Antibiotic prophylaxis in patients with cirrhosis: current evidence for clinical practice.

To Professor

Lian-Sheng Ma,

Company Editor-in-Chief

To Professors

Ke-Qin Hu, Koo Jeong Kang, Nikolaos Pyrsopoulos

Editors-in-Chief

World Journal Hepatology

Verona, 8th June 2021

Dear Editors,

We would like to thank for the opportunity to re-submit this manuscript for *World Journal Hepatology*.
The manuscript has been reviewed according to requested corrections.

Best Regards

Dr. Alberto Ferrarese, MD

Gastroenterology

Azienda Ospedaliera Universitaria Integrata

Verona

REPARTO: TEL. 045 8122305 - ENDOSCOPIA DIGESTIVA: TEL. 045 8122420-2417 - DAY HOSPITAL: TEL. 045 8122303
FISIOPATOLOGIA DIGESTIVA: TEL. 045 8123517-3146 - ECOGRAFIA: TEL. 045 8122308



UNITÀ OPERATIVA CON SISTEMA QUALITÀ UNI EN ISO 9001:2008 - Certificato n. 194114

Reviewer Comments to Author

Reviewer#1

A very concise, comprehensive and well-written review. I have a few comments though to the authors. I think it is important to debate/underline a little bit more about the adverse events of antibiotic prophylaxis like the increasing incidence of Clostridioides difficile infection associated with increased morbidity and mortality in cirrhotic patients.

We thank for the valuable comment.

The section about adverse events of antibiotic prophylaxis, and in particular the risk of *Clostridioides difficile* infection, has been widened in the revised version of the manuscript.

Updated references^[1-4] have been added, accordingly.

1 Fernández J, Piano S, Bartoletti M, Wey EQ. Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. *J Hepatol* 2021; **75 Suppl 1**: S101-S117 [PMID: 34039482 DOI: 10.1016/j.jhep.2020.11.010]

2 Kim D, Yoo ER, Li AA, Tighe SP, Cholankeril G, Ahmed A. Trends in Hospitalizations for Clostridioides difficile Infection in End-Stage Liver Disease, 2005-2014. *Dig Dis Sci* 2021; **66**(1): 296-307 [PMID: 32124196 DOI: 10.1007/s10620-020-06162-0]

3 Dotson KM, Aitken SL, Sofjan AK, Shah DN, Aparasu RR, Garey KW. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. *Epidemiol Infect* 2018; **146**(9): 1101-1105 [PMID: 29739486 PMCID: PMC6057822 DOI: 10.1017/S0950268818001036]

4 Pringle PL, Soto MT, Chung RT, Hohmann E. Patients With Cirrhosis Require More Fecal Microbiota Capsules to Cure Refractory and Recurrent Clostridium difficile Infections. *Clin Gastroenterol Hepatol* 2019; **17**(4): 791-793 [PMID: 29859984 DOI: 10.1016/j.cgh.2018.05.038]